Overall rank by patents
#14,148
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Mycovia Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 21 granted patents across 9 technology areas, active 2018–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
21
Total patents granted
9
CPC technology areas
10.8
Avg claims per patent
-60%
5-year filing velocity
The verdict
Mycovia holds 21 US patents across 9 technology areas, rank #14,148 of 50,000 tracked assignees.
- #14,148
- of 50,000 US assignees by volume
- Top 74%
- by Innovation Score (28.2/100)
- 10.8
- avg claims per patent
- -60%
- filing velocity, last 5 yrs
Portfolio overview
Mycovia Pharmaceuticals, Inc. has been granted 21 US utility patents between 2018 and 2022, placing Mycovia Pharmaceuticals, Inc. at rank #14,148 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.8 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Mycovia Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 28.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 15 in the 2015–2019 window, a -60% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Mycovia Pharmaceuticals, Inc.'s 10.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Mycovia Pharmaceuticals, Inc. against peers pursuing similar technology classes.
How does Mycovia compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Mycovia Pharmaceu… ◀ 21
Mycovia Pharmaceuticals, Inc.
21 patents
What this shows Mycovia holds 21 patents, placing it at rank #14,148 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Mycovia's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 74% higher than 26% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2018–2022
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 4 | 19.0% |
| 2019 | 11 | 52.4% |
| 2020 | 4 | 19.0% |
| 2021 | 1 | 4.8% |
| 2022 | 1 | 4.8% |
Which technologies does Mycovia Pharmaceuticals, Inc. patent most?
Top 9 of 9 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Declining
Frequently Asked Questions
How many patents does Mycovia Pharmaceuticals, Inc. hold?
Mycovia Pharmaceuticals, Inc. holds 21 US granted patents filed between 2018 and 2022, spanning 9 technology areas.
What is Mycovia Pharmaceuticals, Inc.'s Innovation Score?
Mycovia Pharmaceuticals, Inc. has an Innovation Score of 28.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Mycovia Pharmaceuticals, Inc. focus on?
Mycovia Pharmaceuticals, Inc.'s top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 21 patents. The company has filed patents in 9 CPC subclasses total.
Is Mycovia Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Mycovia Pharmaceuticals, Inc.'s recent filing velocity is -60% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Mycovia Pharmaceuticals, Inc.'s patents?
Mycovia Pharmaceuticals, Inc.'s patents average 10.8 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Mycovia Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Mycovia's 21 grants land it in the top 74% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Mycovia ranks #14,148 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07D - see who else leads that technology area. C07D leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
C07D technology
Mycovia Pharmaceuticals, Inc.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Mycovia Pharmaceuticals, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
